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Fusion proteins can be used directly in protein crystallization to assist
crystallization in at least two different ways. In one approach, the ‘heterologous
fusion-protein approach’, the fusion partner can provide additional surface area
to promote crystal contact formation. In another approach, the ‘fusion of
interacting proteins approach’, protein assemblies can be stabilized by
covalently linking the interacting partners. The linker connecting the proteins
plays different roles in the two applications: in the first approach a rigid linker is
required to reduce conformational heterogeneity; in the second, conversely, a
flexible linker is required that allows the native interaction between the fused
proteins. The two approaches can also be combined. The recent applications of
fusion-protein technology in protein crystallization from the work of our own
and other laboratories are briefly reviewed.
1. Introduction and overview
Recombinant fusion proteins (also termed chimeric or hybrid
proteins) are used widely in a variety of protein-engineering
applications ranging from tags to facilitate protein purification
and detection to therapeutics and nanotechnology (Yu et al.,
2015; Bell et al., 2013). Most proteins used for protein crys-
tallization are obtained recombinantly as fusion proteins with
tags for affinity chromatography (Derewenda, 2004). The use
of tagged proteins has been further popularized by structural
genomics initiatives (Gra¨slund et al., 2008).
1.1. The use of fusion proteins for crystallization
Typically, fusion tags are removed from the target protein
before crystallization (Derewenda, 2004; Waugh, 2005). In the
case of short affinity tags (such as the Strep-tag or the poly-
histidine tag in the absence of metal ion), tag removal may be
favoured owing to the fact that the tags often do not have a
defined three-dimensional structure and could represent an
entropic impediment to crystallization and shield the protein
surface from forming crystal contacts. Limited data exist to
establish the general validity of these arguments, however,
aside from anecdotal examples showing the requirement of tag
removal for crystallization or improved diffraction quality
(see, for example, Kim et al., 2001; Huh et al., 2014; Sugawara
et al., 2005). Bucher et al. (2002) examined the effect of
different tags on the crystallization of Pyrococcus furiosus
maltodextrin-binding protein, demonstrating that the tags
can have significant effects on crystallization and diffraction
quality. In the proteins crystallized with a short fusion tag
present, the fusion tag is rarely observed in the electron-
density maps (Carson et al., 2007). Larger affinity tags [such as
glutathione-S-transferase (GST) or maltose-binding protein
(MBP)] have a defined three-dimensional structure. However,
the protein and its fusion partner will usually not associate in
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any defined way, causing conformational flexibility and
hindering crystallization. These effects are exacerbated by the
linker sequences typically containing protease-cleavage sites
for tag removal; they are therefore optimized for easy access
of the protease through increased length and flexibility. Even
though the fusion partner (in particular in the case of large
fusion tags) may improve the solubility properties of the
protein, which may be advantageous for crystallization, the
conformational heterogeneity introduced by the fusion
partner will generally have an overwhelmingly negative effect.
Nevertheless, fusion proteins can be useful in protein
crystallization in specific cases. Fundamentally, there are at
least two ways in which one can take advantage of intact
fusion proteins in the protein crystallization process (Fig. 1).
In one approach, a fusion partner can provide an additional
surface area that can contribute to crystal contact formation
(Fig. 1a); here, we term this approach the ‘heterologous
fusion-protein approach’, as the fusion partner will usually be
a heterologous fusion tag such as MPB or T4 lysozyme (T4L).
This approach can be especially powerful in the case of inte-
gral membrane proteins, where polar surface areas that are
favourable for crystal contact formation may be scarce. In a
fundamentally different application, one can covalently link
interacting proteins to promote their interaction by increasing
their local concentration and controlling the stoichiometry
(Fig. 1b). Here, we term this approach the ‘fusion of inter-
acting proteins approach’. As we illustrate below, these
applications can also be combined. Whereas these strategies
are in general applicable to any protein target, targeted
variations have also been developed for specific proteins or
protein families. We review the fusion-protein strategies in
protein crystallization and illustrate them using specific
representative examples. We refer to other recent reviews for
more comprehensive coverage of particular aspects of the
topic of this article.
1.2. The role of fusion-protein linkers
The linker plays fundamentally different roles in the
heterologous fusion-protein and fusion of interacting proteins
approaches. In the heterologous fusion-protein application a
rigid connection between the fusion partners is desired to
eliminate the conformational heterogeneity caused by the
fusion, whereas when fusing interacting proteins the linker has
to be of sufficient length and flexible enough not to interfere
with the native interaction between the partners (Fig. 1). To
help with the choice of linkers, researchers have analyzed
natural linkers that occur between domains in multi-domain
proteins. An early analysis suggested that natural interdomain
linkers are rich in Thr, Ser, Gly and Ala residues (Argos,
1990). However, a more recent analysis of a larger set of
structures found a very different composition, with Pro, Arg,
Phe, Thr, Glu and Gln the preferred amino-acid residues
(George & Heringa, 2002). Just like artificial linkers in
recombinant fusion proteins, the natural linkers may obviously
play two fundamentally different roles; in some cases they may
serve as rigid spacers to prevent unfavourable interactions
between domains, whereas in others they may have to be
flexible in order to not interfere with interdomain interactions
and domain movement. It is likely that the data set in the
former study was enriched in flexible linkers, whereas that
in the latter study contained more proteins containing rigid
linkers, biasing the outcomes in each case. Ideally, such
analyses should divide the data depending on the function of
the linker, although this may create new challenges. Never-
theless, we can learn from natural linkers when optimizing
the composition and length of linkers in recombinant fusion
constructs.
2. Heterologous fusion-protein approach
The possible benefits of using a fusion protein with a hetero-
logous fusion partner in crystallization include (i) additional
surface areas that can help in crystal contact formation
(especially if the fusion partners crystallize readily them-
selves) and (ii) knowledge of the three-dimensional structure
of the fusion partner for structure determination by molecular
replacement. The approach is therefore analogous to the
‘crystallization chaperone’ approach, in which an interacting
partner such as an antibody fragment or a designer non-
antibody binding protein such as a DARPin (designed
ankyrin-repeat protein) is used to aid in crystal lattice
formation (Koide, 2009; Derewenda, 2010). Crystallization
chaperones have been particularly valuable in cases of integral
membrane proteins that lack substantial polar surface areas
amenable to crystal contact formation (Hunte & Michel,
2002). However, unlike the crystallization chaperone
approach, the heterologous fusion-protein approach suffers
from conformational heterogeneity introduced by the
unrestrained relative orientations of the fusion partners. Using
fusion to a rigid RNA scaffold to present and help to fold
other RNA sequences is a tool that has also been successfully
employed in RNA crystallization (Zhang & Ferre´-D’Amare´,
2014).
2.1. Early examples of structures of proteins fused to large
fusion partners
Early applications of the heterologous fusion-protein
approach for crystallization explored large fusion partners to
facilitate structural studies of small peptides, taking advantage
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Figure 1
Schematic diagram illustrating (a) the heterologous fusion-protein
approach [the protein of interest (dark) is fused to a heterologous fusion
partner (light) using a short linker (black line)] and (b) the fusion of
interacting proteins approach [the interacting partners are fused
covalently using a linker sequence (black line)].
of the crystal lattice created by the fusion partner (Zhan et al.,
2001; Donahue et al., 1994; Carter et al., 1994). The first
structures of larger proteins containing large fusion partners
used MBP as a fusion partner (Table 1), and most used short
linkers between fusion partners to reduce conformational
flexibility (Center et al., 1998; Smyth et al., 2003); they corre-
sponded to a fragment of the human T-cell leukaemia virus
type 1 (HTLV-1) envelope protein gp21 (Kobe et al., 1999;
Fig. 2a), the Staphylococcus aureus DNA-binding protein
SarR (Liu et al., 2001) and the Saccharomyces cerevisiae
proteins MATa1 (Ke & Wolberger, 2003) and the ribosomal
protein L30 (Chao et al., 2003) (reviewed by Smyth et al.,
2003).
2.2. Recent examples of heterologous fusion-protein
structures of soluble proteins
Despite the potential advantages of the heterologous
fusion-protein approach, the number of reported structures
obtained using such approaches remains relatively low (for
example, less than 100 MBP fusion-protein structures in a total
of 97 000 crystal structures in the PDB). This suggests that
overcoming the conformational heterogeneity problem is
difficult and the approach remains limited to niche applica-
tions. Following the early examples, most cases of hetero-
logous fusion-protein structures have involved MBP as the
fusion partner (for examples, see Moon et al., 2010). Pedersen
and coworkers used surface-entropy reduction to create MBP
variants with superior crystallization properties (Cooper et al.,
2007; Moon et al., 2010) by substituting 2–5 Lys, Asp, Glu and
Asn residues by Ala. This strategy allowed the structure
determination of several structures by the Pedersen labora-
tory (see, for example, Ullah et al., 2008; Bethea et al., 2008;
Mueller et al., 2010) and others (see, for example, Patrick et al.,
2013; Jin et al., 2013; Jung et al., 2014). MBP helps aggregation-
prone proteins to become more soluble (Raran-Kurussi et al.,
2015), but not necessarily monodisperse (Nomine´ et al., 2001),
which could hinder crystallization. Another drawback of using
MBP as the fusion partner may also be its relatively large size
(over 360 residues), limiting the size of the target protein that
can be expressed in Escherichia coli. Fortunately, other
smaller fusion partners have also been used successfully.
For example, a catalytically inactive variant of the Bacillus
amyloliquefaciens ribonuclease barnase was used as a fusion
partner to crystallize the small disulfide-rich cysteine-knot
protein McoEeT1 (Niemann et al., 2005), the green fluorescent
protein (GFP) allowed the crystallization of ubiquitin and the
ubiquitin-binding motif (UBM) of the Y-family polymerase
iota (Suzuki et al., 2010), as well as a fragment of the apoptotic
effector Bax (Czabotar et al., 2013), and an engineered sterile-
 motif (SAM) domain module has been shown to drive the
crystallization of 11 different proteins (Nauli et al., 2007).
Some attributes of selected fusion partners are summarized in
Table 1. A split GFP system has also been engineered for use
as a crystallization partner (Nguyen et al., 2013). Carrier
proteins have even been employed to facilitate the crystal-
lization of antibiotics (Economou et al., 2012).
2.3. Application of the heterologous fusion-protein approach
to integral membrane proteins
As suggested previously, the heterologous fusion-protein
approach could be particularly useful for integral membrane
proteins, where polar surface areas that can support crystal
contact formation are often limited (Prive´ et al., 1994; Smyth et
al., 2003). Although it took some time before these sugges-
tions were realised, with the structure of the 2-adrenergic
receptor (2AR; Rosenbaum et al., 2007), the approach has
proven to be particularly useful in one of the most important
challenges in structural biology: the crystallization of G
protein-coupled receptors (GPCRs). The fusion-protein
strategy applied to 2AR involved T4L (Table 1) inserted into
a flexible intracellular loop of the protein (Rosenbaum et al.,
2007; Figs. 2b and 2c). T4L has been chosen as a well folded
soluble protein that crystallizes under many conditions. Most
crystal structures of GPCRs published to date have been
obtained using the fusion-protein strategy, and the strategy
has also yielded the highest resolution structures of the
proteins in this family (see, for example, Fenalti et al., 2014;
Thorsen et al., 2014; Liu et al., 2012; Cherezov et al., 2007;
Miller-Gallacher et al., 2014). Clearly, tethering the fusion
partner to the GPCR at two ends within a loop could have
reduced some of the conformational heterogeneity usually
associated with fusion proteins; it has recently been shown,
however, that fusing T4L to the N-terminus of a GPCR can
also facilitate crystallization (Zou et al., 2012). Additional
GPCR structures have been obtained using another fusion
partner, the thermostabilized apocytochrome b562RIL (Chun
et al., 2012; Table 1). To further improve the utility of the T4L
fusion approach, the T4L moiety has recently been modified
to decrease its flexibility and size (Thorsen et al., 2014). In one
variant, the flexibility of the two lobes of T4L was reduced by
introducing two disulfide bridges in the interface between the
lobes. In another variant, the smaller N-terminal lobe was
iccbm15
Acta Cryst. (2015). F71, 861–869 Kobe et al.  Fusion-protein-assisted protein crystallization 863
Table 1
Selected heterologous fusion partners.
Fusion partner
Size
(amino acids) Biological origin Selected references
Maltose-binding protein (MBP) 363 Escherichia coli Kobe et al. (1999), Ullah et al. (2008)
Barnase 106 Bacillus amyloliquefaciens Niemann et al. (2005)
Green fluorescent protein (GFP) 221 Aequorea victoria Suzuki et al. (2010)
Sterile- motif (SAM) from the translocation Ets leukaemia protein 78 Homo sapiens Nauli et al. (2007)
T4 lysozyme (T4L) 160 Enterobacteria phage T4 Rosenbaum et al. (2007), Thorsen et al. (2014)
Apocytochrome b562RIL (BRIL) 104 Escherichia coli Liu et al. (2012)
deleted to create a ‘minimal T4L’. Both variants were shown
to improve the diffraction quality of crystals of M3 muscarinic
receptor compared with the unmodified T4L fusion (Thorsen
et al., 2014)
2.4. Hybrid LRR approach and grafting
An ingenious approach to address the conformational
heterogeneity problem of fusion proteins has been introduced
for the class of repeat or solenoid proteins, specifically for
leucine-rich repeat (LRR) proteins, and termed the ‘hybrid
LRR approach’ (Jin & Lee, 2008). The approach takes
advantage of the repeat structure to form a rigid connection
between the fusion partner and the protein of interest. The
approach has been applied successfully to obtain structures of
the extracellular domains of Toll-like receptors (TLRs) 1, 2
and 4 (Jin et al., 2007; Kim et al., 2007; Fig. 2d). The approach
relies on fusing two structurally compatible LRR proteins. For
TLRs, the variable lymphocyte receptor (VLR) from hagfish
was chosen as the fusion partner, as this protein is easy to
produce and crystallize, and its LRRs are structurally similar
to those in TLRs. The two proteins are fused at a conserved
motif in the repeat, so that the repeats can form a continuous
solenoid, eliminating any conformational heterogeneity at the
fusion site. However, choosing the correct fusion site in the
repeats of the two partners does not guarantee comple-
mentarity at the fusion site; a lack of complementarity may
lead to structural collisions or exposure of the hydrophobic
core. For this reason, several hybrids should be tested and
characterized to find a suitable one (Jin & Lee, 2008). In
related work with a somewhat different objective in mind,
namely to create a binding scaffold, a fusion protein was
designed from VLR-based consensus LRRs flanked by the
N-terminal cap from Listeria monocytogenes internalin B and
the C-terminal cap from VLR, and its crystal structure was
determined (Lee et al., 2012).
Another conceptually similar method was used to obtain
structural information on the interaction between the LRR
proteins in the glycoprotein (GP) Ib–IX–V complex involved
in platelet activation and thrombus formation (McEwan et al.,
2011; Kobe, 2011). In this case, McEwan and coworkers
grafted three segments of GPIX onto a portion of the
homologous GPIb, which had been successfully crystallized
previously (McEwan et al., 2011).
2.5. Practical considerations for the heterologous
fusion-protein approach and the choice of linkers
Although the developers of the modified MBP variants
(Moon et al., 2010), the SAM-domain modules (Nauli et al.,
2007) and the hybrid LRR approach (Jin & Lee, 2008) claimed
high success rates for their methods, the scarcity of reported
heterologous fusion-protein structures suggests that success
rates in reality may be low. The key challenges are likely to
correspond to finding a suitable linker that would sufficiently
reduce the conformational heterogeneity of the fusion
protein, and in the case of the hybrid LRR technique the steric
incompatibility at the fusion site. Tethering the fusion partner
at two sites by insertion into a loop, as demonstrated for
GPCRs, may reduce the conformational heterogeneity
problem to some extent. Most successful cases used the MBP
fusion-protein approach and a linker consisting of three
alanine residues (Moon et al., 2010), following an early
successful example (Center et al., 1998); most of the remaining
examples used slightly different sequences of 2–5 residues in
length, and no systematic studies have been performed to date
to our knowledge. Insufficient data are available to draw any
firm conclusions for the other fusion partners. Similarly, other
approaches to constructing rigid linkers, such as using proline-
rich sequences, appear not to have been trialled extensively.
The best strategy for the implementation of the heterologous
fusion-protein approach should therefore take into account
the nature of the target protein. If the method has previously
been applied successfully to a related target protein, for
example in the cases of GPCRs and LRR proteins, the most
effective approach will be to follow the methods that have
proven to be successful for these related proteins. In a more
general case, if the protein is smaller than 400–500 residues
then the MBP-fusion approach using the modified MBP
constructs developed by Pedersen and coworkers (Moon et al.,
2010) and using a short linker of less than five residues in
length may currently be the most effective methodology to
trial. As it is relatively simple to prepare several constructs in
parallel, it should be valuable to systematically trial a number
of linkers, and this should simultaneously increase the overall
chances of success of finding a crystallizable construct.
3. Fusion of interacting proteins approach
In addition to solubilizing one or both interacting partners
when they cannot be expressed on their own, the fusion of
interacting partners addresses the problem of achieving
adequate local concentrations of the binding partners and
maintaining stoichiometry in environments that promote
protein crystallization, so that the interacting complex can be
captured in the crystals. This strategy has proven to be parti-
cularly successful for protein–peptide complexes, although
it has also facilitated the crystallization of several protein–
protein complexes (reviewed by Reddy Chichili et al., 2013b).
One caveat of this fusion-protein strategy is that the linker
may prevent the native association mode; for this reason, the
linker has to be optimized and the fusion protein has to be
characterized, with the observed association mode compared
with the native complex in solution, for example by using
biophysical techniques and site-directed mutagenesis. An
alternative approach to fusing the interacting partners is to
cross-link them; however, this alternative approach comes
with its own challenges, in particular the heterogeneity
introduced by the cross-linking reaction (Reddy Chichili et al.,
2013a; Mouradov et al., 2008; Wine et al., 2007; Leitner et al.,
2010).
3.1. Fusion of protein–peptide complexes
One of the early applications involved the fusion of an
antigen peptide to the N-terminus of the major histocompat-
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ibility complex (MHC) class II 1 chain through a 16-residue
glycine-rich linker (Fremont et al., 1996). An analogous
approach has subsequently been used for a number of other
MHC class II–peptide complexes, as well as T-cell receptor
(TCR)–peptide and TCR–peptide–MHC class II ternary
complexes (Reddy Chichili et al., 2013b). Another successful
example involved the nuclear LIM (Lin-11/Islet-1/Mec-3)
domain-containing zinc-binding transcription factors. An
11-residue Gly/Ser-rich linker was used to link the LIM
domain of LMO4 to the C-terminus of LDB1 (LIM-domain
binding protein 1), facilitating structure determination by both
NMR and crystallography (Deane et al., 2003, 2004). Again,
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Figure 2
Examples of successful application of the heterologous fusion-protein approach. The structures are not shown on the same scale. (a) Cartoon diagram of
the structure of HTLV-1 gp21 (subunits are shown in different colours) fused at the N-terminus to MBP (in different shades of grey) with a three-Ala
linker (red; PDB entry 1mg1; Kobe et al., 1999). (b) Cartoon diagram of the structure of 2-adrenergic receptor (2AR; blue) with T4 lysozyme (T4L;
grey) inserted into a loop in 2AR (Rosenbaum et al., 2007; PDB entry 2rh1). (c) A view of crystal-packing interactions for the 2AR-T4L fusion protein
[shown and coloured as in (b)]. Note the crystal contacts between the fusion partner T4L and the soluble portion of 2AR. (d) Cartoon diagram of the
structure of the complex of the extracellular domains of TLR1 (green) and TLR2 (blue) (Jin et al., 2007; PDB entry 2z7x). Both proteins are fused at the
C-terminus to VLR as the fusion partner (grey). All structure figures were produced with PyMOL (Schro¨dinger).
the strategy has been successfully exploited for a number of
LIM-domain complexes (Reddy Chichili et al., 2013b). Further
examples of structures of fused protein–peptide complexes
include a pregnane X receptor ligand-binding domain
complex with a peptide from the steroid receptor activator 1
(SRC-1; Wang et al., 2008), a paramyxovirus phosphoprotein
complex with a peptide from a nucleocapsid protein (Kingston
et al., 2004), a histone chaperone Asf1 (anti-silencing function
1) complex with a peptide from histone H3 (Antczak et al.,
2006), the West Nile virus protease NS3 tethered to a 40-
residue portion of NS2B (Erbel et al., 2006; Robin et al., 2009),
and a calmodulin complex with a peptide from calcineurin (Ye
et al., 2006). In the latter case, the structure was subsequently
determined using the unlinked peptide and shown to be
identical to the fusion-protein structure (Ye et al., 2008).
3.2. Fusion of protein–protein complexes
Compared with protein–peptide complexes, fewer cases
have been described in which larger interacting protein
domains have been linked to each other. Early examples of
linking domains included glycyl-tRNA synthetase (Toth &
Schimmel, 1986), immunoglobulin domains (Bird et al., 1988;
Huston et al., 1988) and an HIV protease homodimer (Cheng
et al., 1990). The main objective for the HIV protease work
was to allow modification of one of the subunits so that effects
on the enzymatic activity could be assessed. However, the
fusion was also found to stabilize the dimer interaction at pH
values where the subunits dissociated in the wild-type protein.
The structure of the single-chain dimer turned out to be
identical to the natural dimer except near the linker region
(Bhat et al., 1994). Two subunits were similarly linked in
transthyretin to stabilize its assembly (Foss et al., 2005).
Another example involved the linkage of two domains from
the ionotropic glutamate receptor that are separated by
transmembrane segments in the wild-type protein; the
construct retained its ligand-binding ability (Armstrong &
Gouaux, 2000). The crystal structure of the complex between
the Ff bacteriophage minor coat gene 3 protein (g3p) N1
domain and the E. coli TolA C-terminal domain was obtained
by fusing these domains with a long flexible linker (Lubkowski
et al., 1999). Park & Hol (2012) explored various linkages
between the OB-fold domain-containing proteins interacting
within the editosome complex from Trypanosoma brucei.
Testing 25 different expression and co-expression experi-
ments, which included up to four linked domains, resulted in
one crystal structure corresponding to two proteins linked
through a nine-residue linker (Park & Hol, 2012; Fig. 3a).
We have successfully applied the interaction protein-fusion
strategy to the family of TIR (Toll/interleukin-1 receptor/
resistance protein) domains found in diverse proteins involved
in immune signalling from mammals to plants (Ve et al., 2015).
These domains are thought to signal through self-association
or homotypic interactions with TIR domains from other
proteins. Most reported dissociation constants for TIR–TIR
domain interactions are in the micromolar range, and the
transient nature of these interactions has made it difficult to
define the interfaces between interacting TIR domains using
X-ray crystallography. We applied the strategy to a number
of TIR domains from both mammalian and plant immune
proteins, and found that the addition of linkers between TIR
domains facilitated the expression and purification of most of
the TIR–TIR domain complexes investigated, improving the
yield of soluble protein, and in two cases enabled the
production of a soluble TIR domain that could not be
produced in a soluble form by itself (Williams et al., 2015). We
obtained crystals of two TIR–TIR domain complexes, one
yielding a high-resolution structure of the first heterodimeric
TIR-domain complex [of the TIR domains from the Arabi-
dopsis thaliana nucleotide-binding/LRR (NLR) proteins
RPS4 and RRS1; Fig. 3b; Williams et al., 2014]. The biological
relevance of the observed association was validated through
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Figure 3
Examples of successful application of the fusion of interacting proteins approach. The structures are not shown on the same scale. (a) Cartoon diagram of
the structure of the OB-fold domains from the editosome proteins A3 (blue) and A6 (green) linked with a nine-residue linker (red) (Park & Hol, 2012;
PDB entry 4dni). (b) Cartoon diagram of the structure of the linked TIR domains from RRS1 (green) and RPS4 (cyan) (Williams et al., 2014; PDB entry
4c6t). There was no interpretable electron density corresponding to the five-residue linker and flanking residues; therefore, it is not clear which domains
are linked in the crystal. Nevertheless, the structure revealed a biologically meaningful interdomain interface (Williams et al., 2014). In the figure, the
domain termini that are linked in the fusion protein are labelled with red asterisks.
small-angle X-ray scattering and site-directed mutagenesis
followed by functional assays (Williams et al., 2014).
3.3. Practical considerations for the fusion of interacting
proteins approach and the choice of linkers
Insufficient successful examples of the fusion of interacting
proteins approach exist to extract a generic set of guidelines
that could lead to successful application with a high chance of
success. As suggested above for the heterologous fusion-
protein approach, the most effective strategy in cases where
the approach has been successfully applied to related proteins
is to follow what worked in these cases; this has been
successfully exploited in the cases of MHC class II and LMO-
domain proteins. The approach will clearly have to be opti-
mized in each specific case to identify the appropriate length
of the linker, so that the native association mode can be
retained; any prior knowledge should be used to estimate the
approximate length required (considering an 3 A˚ span per
residue in an extended structure). Most successful examples
have used Gly/Ser/Thr-rich linkers of 2–31 residues in length,
with most in the 5–11-residue range (for an extensive list of
examples, see Reddy Chichili et al., 2013b). Such a linker
composition ensures that the sequence is flexible, hydrophilic
and resistant to proteolysis.
Because the linker can potentially interfere with the native
association, it is extremely important that the fusion construct
is characterized and the observed association compared with
the association of unlinked components in solution. This can
be achieved through the use of a variety of biophysical and
biophysical methods [for example, size-exclusion chromato-
graphy (SEC) combined with multi-angle laser light scattering
(MALS), small-angle X-ray scattering (SAXS), chemical
cross-linking followed by mass spectrometry (MS), hydrogen/
deuterium-exchange NMR or mass spectrometry] and the
effects of mutations of the residues observed in the interface
can be tested by functional assays.
The fusion of interacting proteins approach can clearly lead
to an intermolecular, rather than an intramolecular, inter-
action between the linked partners (equivalent to domain
swapping; Gronenborn, 2009). For example, this occurred in
the paramyxovirus phosphoprotein-nucleocapsid protein
fusion construct (Kingston et al., 2004) and is likely to have
occurred in the RPS4-RRS1 TIR-domain fusion (Williams et
al., 2014, 2015). Such an outcome could be promoted through
the wrong choice of linker length (in particular if the linker is
too short and the native intramolecular association cannot
occur). This outcome can easily be detected by measuring the
molecular mass of the fusion protein (ideally by methods
that determine the mass independent from the shape of the
molecule, such as MALS), although domain swapping may
also be induced by crystallization itself. It is important to note
that such an outcome may not necessarily prevent meaningful
biological interpretations about the association mode;
however, the observed association needs to be thoroughly
validated, as described above.
4. Combination of the two approaches
An interesting application of fusion-protein technology, which
combines both the heterologous fusion-protein and fusion of
interacting proteins approaches discussed above, has been
pioneered by Pornillos et al. (2009). Owing to difficulties in
capturing hexamers of the HIV capsid protein in crystals,
these researchers fused the hexameric protein CcmK4 to the
target protein and successfully determined the crystal struc-
ture of the capsid hexamer. This strategy combines the
advantages of the two fusion-protein approaches, with the
hexameric arrangement of the heterologous fusion partner
bringing together the weakly interacting target proteins.
Interestingly, in the crystals of the HIV capsid-CcmK4 fusion
no interpretable electron density for the CcmK4 moiety was
observed, despite an only two-residue linker between the two
proteins, suggesting that the fusion partner occupied multiple
positions in the crystal. An analogous strategy was used to
crystallize the type II secretion system ATPase GspEEpsE from
Vibrio cholerae. By fusing GspEEpsE with the Pseudomonas
aeruginosa hexamer-forming secretion-system protein Hcp1,
the active hexametric structure could be determined (Lu et al.,
2013; Fig. 4). In this case the fusion protein could be located in
the crystals. Fusion of a crystallization chaperone, for example
a designer binding protein such as a DARPin, to the protein of
interest would be another interesting combination of the two
approaches.
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Figure 4
Example of the combination of the heterologous fusion-protein and
fusion of interacting proteins approaches. The type II secretion system
ATPase GspEEpsE from V. cholerae was fused at the C-terminus to the
P. aeruginosa hexamer-forming secretion-system protein Hcp1 (Lu et al.,
2013; PDB entry 4kss). In the cartoon diagram of the hexameric complex,
the individual subunits of GspEEpsE are shown in different colours and
individual subunits of Hcp1 are shown in alternating dark and light grey.
The linkers between the fusion partners have not been modelled. The N-
and C-termini of the proteins are at the top and the bottom of the
structure, respectively.
5. Conclusions
Even though most proteins used for protein crystallization are
produced as recombinant proteins fused to affinity tags to
facilitate efficient purification and to enhance folding and
solubility, the tags are generally removed before crystal-
lization and fusion proteins are rarely used in crystallization.
However, in this article we illustrate approaches that take
advantage of fusion-protein technology in crystallization itself,
in particular the heterologous fusion-protein and fusion of
interacting proteins approaches. Crystallization is clearly one
of the major bottlenecks of macromolecular crystallography,
and one must attack the problem on multiple fronts, especially
in difficult cases such as membrane proteins and weakly
interacting protein complexes. The key to the choice of the
most promising approaches for a particular macromolecule or
complex is in understanding its chemical and physical prop-
erties. We believe appropriate fusion-protein approaches
described here should be considered, especially in cases where
other approaches have not led to success.
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